Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-38 in AML and Multiple Myeloma
NCT05442580Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- May 2023
- Primary completion
- Feb 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART-38 in acute myeloid leukemia (AML) and multiple myeloma (MM), sponsored by University of Pennsylvania. Started May 2023; status: terminated.
02
Drugs
CART-38
03
Conditions
acute myeloid leukemia (AML)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05442580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442580.